Taiyo Kosan Co., Ltd. submitted an amended tender offer notification to the Kanto Finance Bureau on February 3, 2026, regarding the tender offer it commenced on January 7, 2026, for shares of Hisamitsu Pharmaceutical Co., Inc., partially correcting the tender offer commencement announcement.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4530","jir_company_name":"Hisamitsu Pharmaceutical Co., Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4530-20260203-01.pdf","jir_short_summary":"Taiyo Kosan Co., Ltd. submitted an amended tender offer notification to the Kanto Finance Bureau on February 3, 2026, regarding the tender offer it commenced on January 7, 2026, for shares of Hisamitsu Pharmaceutical Co., Inc., partially correcting the tender offer commencement announcement.","jir_summary":"### Overview of the Tender Offer and Details of the Correction\nTaiyo Kosan Co., Ltd. commenced a tender offer on January 7, 2026, for common shares, stock acquisition rights, and depositary receipts for shares of Hisamitsu Pharmaceutical Co., Inc. Due to the expiration of the waiting period under U.S. antitrust laws, certain items described in the tender offer notification dated January 7, 2026 (and the amendment dated January 14), required correction. Consequently, on February 3, 2026, an amended notification was submitted to the Kanto Finance Bureau. The corrections involve partial revisions to the tender offer commencement announcement and do not include any changes to the offer conditions.\n\n### Impact on Investors and Cautions\nThis tender offer is conducted under Japanese law and thus procedures and disclosure standards differ from those under U.S. securities laws. This is not a solicitation for sale; shareholders must review the tender offer explanatory statement and make their own decisions regarding participation. Additionally, the tender offeror and related parties may acquire shares outside the market, and there are uncertainties related to forward-looking statements. Investors are advised to consider this information carefully and respond with caution.","jir_financial_highlights":"Tender Offer Commencement Date: 2026\u5e741\u67087\u65e5 (Unknown)\nTender Offer Notification Amendment Date: 2026\u5e742\u67083\u65e5 (Unknown)\nTarget Securities: Hisamitsu Pharmaceutical Co., Inc. Common Shares, Stock Acquisition Rights, Depositary Receipts for Shares (Unknown)","jir_category":"","jir_hashtags":"#HisamitsuPharmaceutical, #TenderOffer, #TOB, #JapaneseStocks","jir_key_figures":"Tender Offer Commencement Date: 2026\u5e741\u67087\u65e5\nTender Offer Notification Amendment Submission Date: 2026\u5e742\u67083\u65e5\nTarget Securities: Common shares, stock acquisition rights, and depositary receipts for shares of Hisamitsu Pharmaceutical Co., Inc.","jir_meta_title":"Correction to the Notice of Tender Offer Commencement by Taiyo Kosan Co., Ltd. for Hisamitsu Pharmaceutical Co., Inc. (February 3, 2026)","jir_meta_description":"Taiyo Kosan Co., Ltd. submitted an amended tender offer notification on February 3, 2026, regarding the tender offer for shares of Hisamitsu Pharmaceutical Co., Inc., which began on January 7, 2026, partially correcting the announcement.","jir_og_title":"Notice of Correction to the Tender Offer Commencement Announcement for Hisamitsu Pharmaceutical Co., Inc. (February 3, 2026)","jir_og_description":"Information regarding the correction of the notification and announcement related to the tender offer by Taiyo Kosan Co., Ltd. for Hisamitsu Pharmaceutical Co., Inc.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8125,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-23850","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n